SciBase Holding AB (FRA:5J3) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5J3 SciBase Holding AB FRA:5J3
56 GF Score
Price €1.64
GF Value €1.06
! 4 Warning Signs
View Full Analysis

What is SciBase Holding AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:5J3
56GF Score
SciBase Holding AB FRA:5J3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SciBase Holding AB (FRA:5J3) Overvalued in 2026?

Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued. The current stock price of €1.64 is trading 54.7% above its estimated GF Value™ of €1.06.

Key valuation signals for FRA:5J3:

  • FFO:
  • GF Value™: €1.06 vs. price of €1.64 (54.7% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:5J3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SciBase Holding AB Business Description

Other Exchanges SCIB:Sweden
Address Landsvagen 39, Sundbyberg, Stockholm, SWE, 172 63
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
56GF Score

Get the complete analysis for FRA:5J3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64
Price
€1.06
GF Value